Lead Plaintiff Deadline: October 17, 2022
Please Upload related files below
Fill in below.
Looking for more?
common stock between December 29, 2020 and August 3, 2022
(i) defendants had inflated the Company’s true ability to successfully file a Biologics License Application (“BLA”) for Ampion; (ii) defendants had inflated the results of the AP-013 study and the timing of unblinding the data from the AP-013 study; and (iii) as a result of the foregoing, defendants’ statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
In order to be included in the lawsuit, you must have incurred a loss on shares of Ampio, either: A) purchased or acquired during the class period listed above, if applicable; or B) pursuant to the Initial Public Offering (IPO) of Ampio, if applicable.
If you suffered a loss in Ampio during the relevant time frame, or pursuant to Ampio’s IPO if listed above, you have until October 17, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.